Department of Cardiology Erasmus MC, University Medical Center Rotterdam The Netherlands.
Department of Cardiothoracic Surgery Erasmus MC, University Medical Center Rotterdam The Netherlands.
J Am Heart Assoc. 2022 Nov 15;11(22):e025121. doi: 10.1161/JAHA.121.025121. Epub 2022 Nov 8.
Background The objective of this international multicenter study was to investigate both early and late outcomes of cardiac resynchronization therapy (CRT) in patients with a systemic right ventricle (SRV) and to identify predictors for congestive heart failure readmissions and mortality. Methods and Results This retrospective international multicenter study included 13 centers. The study population comprised 80 adult patients with SRV (48.9% women) with a mean age of 45±14 (range, 18-77) years at initiation of CRT. Median follow-up time was 4.1 (25th-75th percentile, 1.3-8.3) years. Underlying congenital heart disease consisted of congenitally corrected transposition of the great arteries and dextro-transposition of the great arteries in 63 (78.8%) and 17 (21.3%) patients, respectively. CRT resulted in significant improvement in functional class (before CRT: III, 25th-75th percentile, II-III; after CRT: II, 25th-75th percentile, II-III; =0.005) and QRS duration (before CRT: 176±27; after CRT: 150±24 milliseconds; =0.003) in patients with pre-CRT ventricular pacing who underwent an upgrade to a CRT device (n=49). These improvements persisted during long-term follow-up with a marginal but significant increase in SRV function (before CRT; 30%, 25th-75th percentile, 25-35; after CRT: 31%, 25th-75th percentile, 21-38; =0.049). In contrast, no beneficial change in the above-mentioned variables was observed in patients who underwent de novo CRT (n=31). A quarter of all patients were readmitted for heart failure during follow-up, and mortality at latest follow-up was 21.3%. Conclusions This international experience with CRT in patients with an SRV demonstrated that CRT in selected patients with SRV dysfunction and pacing-induced dyssynchrony yielded consistent improvement in QRS duration and New York Heart Association functional status, with a marginal increase in SRV function.
本国际多中心研究旨在探讨伴有系统性右心室(SRV)的心脏再同步治疗(CRT)的早期和晚期结果,并确定充血性心力衰竭再入院和死亡率的预测因素。
本回顾性国际多中心研究纳入了 13 个中心。研究人群包括 80 例伴有 SRV 的成年患者(48.9%为女性),在开始 CRT 时的平均年龄为 45±14 岁(范围,18-77 岁)。中位随访时间为 4.1 年(25-75 百分位,1.3-8.3 年)。先天性心脏病包括矫正性大动脉转位 63 例(78.8%)和右旋大动脉转位 17 例(21.3%)。CRT 可显著改善心功能分级(CRT 前:25-75 百分位,II-III;CRT 后:25-75 百分位,II-III;=0.005)和 QRS 时限(CRT 前:176±27 毫秒;CRT 后:150±24 毫秒;=0.003)在接受升级至 CRT 设备的 CRT 前有室性起搏的患者(n=49)。这些改善在长期随访中持续存在,SRV 功能有轻微但显著的增加(CRT 前:30%,25-75 百分位,25-35;CRT 后:31%,25-75 百分位,21-38;=0.049)。相比之下,在接受初次 CRT 的患者(n=31)中,上述变量未见有益变化。在随访期间,所有患者中有四分之一因心力衰竭再入院,最新随访时的死亡率为 21.3%。
本国际伴有 SRV 的 CRT 经验表明,在伴有 SRV 功能障碍和起搏诱导的不同步的选定患者中,CRT 可一致改善 QRS 时限和纽约心脏协会心功能状态,SRV 功能有轻微增加。